Download PDF
Synlett 2007(8): 1177-1189  
DOI: 10.1055/s-2007-973893
ACCOUNT
© Georg Thieme Verlag Stuttgart · New York

Exploring Chemical Space with Organometallics: Ruthenium Complexes as Protein Kinase Inhibitors

Eric Meggers*, G. Ekin Atilla-Gokcumen, Howard Bregman, Jasna Maksimoska, Seann P. Mulcahy, Nicholas Pagano, Douglas S. Williams
Department of Chemistry, University of Pennsylvania, 231 South 34th Street, Philadelphia, PA 19104, USA
Fax: +1(215)7460348; e-Mail: meggers@sas.upenn.edu;
Further Information

Publication History

Received 28 August 2006
Publication Date:
03 April 2007 (online)

    Permissions and Reprints All articles of this category

Abstract

Complementing organic elements with a metal center provides new opportunities for building three-dimensional structures with unique and defined shapes. Such access to unexplored chemical space may lead to the discovery of molecules with unprecedented properties. Along these lines, this account article describes our successful design of highly potent and selective ruthenium-based inhibitors for the protein kinases GSK-3 and Pim-1 by using the class of indolocarbazole alkaloids as a lead structure. The described ruthenium complexes are kinetically inert scaffolds in which the ruthenium has the function to organize the orientation of the organic ligands in the three-dimensional space.

  • 1 Introduction

  • 1.1 Biologically Relevant Chemical Space

  • 1.2 Organic vs. Organometallic Compounds

  • 1.3 Ruthenium as a Virtual Octahedral Carbon

  • 2 Mimicking the Natural Product Staurosporine with Simple Ruthenium Complexes

  • 3 Synthesis of Cycloruthenated Pyrido[2,3-a]pyrrolo[3,4-c]carbazole-5,7(6H)-diones

  • 4 Discovery of Ruthenium Complexes as Protein Kinase ­Inhibitors

  • 4.1 Octahedral Complexes

  • 4.2 Half-Sandwich Complexes

  • 5 Structures of Ruthenium Half-Sandwich Complexes Bound to Protein Kinase Pim-1

  • 6 GSK-3 Inhibition in Mammalian Cells, Frog Embryos, and Zebrafish Embryos

  • 7 Summary and Outlook

Key words

bioorganometallic chemistry - protein kinases - inhibitors - ruthenium - mammalian cells

    References and Notes

  • See, for example:
  • 1a Schreiber SL. Bioorg. Med. Chem.  1998,  6:  1127 
    CrossrefGoogle Scholar
  • 1b Mayer TU. Trends Cell Biol.  2003,  13:  270 
    CrossrefGoogle Scholar
  • 1c Ding S. Schultz PG. Nature Biotechnol.  2004,  22:  833 
    CrossrefGoogle Scholar
  • For chemical space, see:
  • 2a Burke MD. Schreiber SL. Angew. Chem. Int. Ed.  2004,  43:  46 
    CrossrefGoogle Scholar
  • 2b Dobson CM. Nature (London)  2004,  432:  824 
    CrossrefGoogle Scholar
  • 2c Lipinski C. Hopkins A. Nature (London)  2004,  432:  855 
    CrossrefGoogle Scholar
  • 2d Koch MA. Schuffenhauer A. Scheck M. Wetzel S. Casaulta M. Odermatt A. Ertl P. Waldmann H. Proc. Natl. Acad. Sci. U.S.A.  2005,  102:  17272 
    CrossrefGoogle Scholar
  • For bioorganometallic and medicinal organometallic chemistry, see:
  • 4a Severin K. Bergs R. Beck W. Angew. Chem. Int. Ed.  1998,  37:  1634 
    CrossrefGoogle Scholar
  • 4b Grotjahn DB. Coord. Chem. Rev.  1999,  190-192:  1125 
    CrossrefGoogle Scholar
  • 4c Jaouen G., Ed.; J. Organomet. Chem.  1999,  589:  1 
    CrossrefGoogle Scholar
  • 4d Metzler-Nolte N. Angew. Chem. Int. Ed.  2001,  40:  1040 
    CrossrefGoogle Scholar
  • 4e Fish RH. Jaouen G. Organometallics  2003,  22:  2166 
    CrossrefGoogle Scholar
  • 4f Stodt R. Gencaslan S. Müller IM. Sheldrick WS. Eur. J. Inorg. Chem.  2003,  1873 
    CrossrefGoogle Scholar
  • 4g Schlawe D. Majdalani A. Velcicky J. Heßler E. Wieder T. Prokop A. Schmalz H.-G. Angew. Chem. Int. Ed.  2004,  43:  1731 
    CrossrefGoogle Scholar
  • 4h Van Staveren DR. Metzler-Nolte N. Chem. Rev.  2004,  104:  5931 
    CrossrefGoogle Scholar
  • 4i Ott I. Kircher B. Gust R. J. Inorg. Biochem.  2004,  98:  485 
    CrossrefGoogle Scholar
  • 4j Bioorganometallics   Jaouen G. Wiley-VCH; Weinheim: 2005. 
    CrossrefGoogle Scholar
  • 4k Yan YK. Melchart M. Habtemariam A. Sadler PJ. Chem. Commun.  2005,  4764 
    CrossrefGoogle Scholar
  • 4l Allardyce CS. Dorcier A. Scolaro C. Dyson PJ. Appl. Organomet. Chem.  2005,  19:  1 
    CrossrefGoogle Scholar
  • 4m Dyson PJ. Sava G. Dalton Trans.  2006,  1929 
    CrossrefGoogle Scholar
  • 4n Schatzschneider U. Metzler-Nolte N. Angew. Chem. Int. Ed.  2006,  45:  1504 
    CrossrefGoogle Scholar
  • Some examples of using metals for structural roles in protein binders. See:
  • 5a Lebon F. De Rosny E. Reboud-Ravaux M. Durant F. Eur. J. Med. Chem.  1998,  33:  733 
    CrossrefGoogle Scholar
  • 5b Lebon F. Ledecq M. Benatallah Z. Sicsic S. Lapouyade R. Kahn O. Garcon A. Reboud-Ravaux M. Durant F. J. Chem. Soc., Perkin Trans. 2  1999,  795 
    CrossrefGoogle Scholar
  • 5c Cherrier MV. Martin L. Cavazza C. Jacquamet L. Lemaire D. Gaillard J. Fontecilla-Camps JC. J. Am. Chem. Soc.  2005,  127:  10075 
    CrossrefGoogle Scholar
  • For a strategy of targeting metal complexes to enzyme active sites, see:
  • 6a Wilker JJ. Dmochowski IJ. Dawson JH. Winkler JR. Gray HB. Angew. Chem. Int. Ed.  1999,  38:  90 
    CrossrefGoogle Scholar
  • 6b Dmochowski IJ. Crane BR. Wilker JJ. Winkler JR. Gray HB. Proc. Natl. Acad. Sci. U.S.A.  1999,  96:  12987 
    CrossrefGoogle Scholar
  • 6c Dunn AR. Dmochowski IJ. Winkler JR. Gray HB. J. Am. Chem. Soc.  2003,  125:  12450 
    CrossrefGoogle Scholar
  • 6d Dunn AR. Belliston-Bittner W. Winkler JR. Getzoff ED. Stuehr DJ. Gray HB. J. Am. Chem. Soc.  2005,  127:  5169 
    CrossrefGoogle Scholar
  • 7 Zhang L. Carroll PJ. Meggers E. Org. Lett.  2004,  6:  521 
    CrossrefGoogle Scholar
  • 8 Bregman H. Williams DS. Atilla GE. Carroll PJ. Meggers E. J. Am. Chem. Soc.  2004,  126:  13594 
    CrossrefGoogle Scholar
  • 9 Williams DS. Atilla GE. Bregman H. Arzoumanian A. Klein PS. Meggers E. Angew. Chem. Int. Ed.  2005,  44:  1984 
    CrossrefGoogle Scholar
  • 10 Bregman H. Williams DS. Meggers E. Synthesis  2005,  1521 
    Article in Thieme ConnectGoogle Scholar
  • 11 Debreczeni J. Bullock AN. Atilla GE. Williams DS. Bregman H. Knapp S. Meggers E. Angew. Chem. Int. Ed.  2006,  45:  1580 
    CrossrefGoogle Scholar
  • 12 Bregman H. Carroll PJ. Meggers E. J. Am. Chem. Soc.  2006,  128:  877 
    CrossrefGoogle Scholar
  • 13 Atilla-Gokcumen GE. Williams DS. Bregman H. Pagano N. Meggers E. ChemBioChem  2006,  7:  1443 
    CrossrefGoogle Scholar
  • 14 Hypervalent carbon exists but cannot be exploited for structural chemistry. See for example pentacoordinated carbon in form of highly reactive carbonium ions: Olah GA. Angew. Chem. Int. Ed.  1995,  34:  1393 
    Google Scholar
  • Nonmetallic elements of the third row or higher can form stable penta- and hexacoordinated geometries. See, for example:
  • 15a Martin JC. Science  1983,  221:  509 
    CrossrefGoogle Scholar
  • 15b Holmes RR. Chem. Rev.  1996,  96:  927 
    CrossrefGoogle Scholar
  • 16 Taube H. Chem. Rev.  1952,  50:  69 
    CrossrefGoogle Scholar
  • 17 The cysteine-containing tripeptide glutathione is present in virtually all mammalian cells at millimolar concentrations: Kaplowitz N. Aw TY. Ookhtens M. Annu. Rev. Pharmacol. Toxicol.  1985,  25:  715 
    CrossrefGoogle Scholar
  • 18 Dwyer FP. Reid IK. Shulman A. Laycock GM. Dixson S. Aust. J. Exp. Biol. Med. Sci.  1969,  47:  203 
    Google Scholar
  • 19a Dwyer FP. Gyarfas EC. Rogers WP. Koch JH. Nature (London)  1952,  170:  190 
    Google Scholar
  • 19b Dwyer FP. Gyarfas EC. Wright RD. Shulman A. Nature (London)  1957,  179:  425 
    Google Scholar
  • 20 For KP1019, see: Hartinger CG. Zorbas-Seifried S. Jakupec MA. Kynast B. Zorbas H. Keppler BK. J. Inorg. Biochem.  2006,  100:  891 
    CrossrefGoogle Scholar
  • 21 For NAMI-A, see: Dyson PJ. Sava G. Dalton Trans.  2006,  16:  1929 
    Google Scholar
  • For clever synthetic strategies of ruthenium complexes, see for example:
  • 22a Gill TP. Mann KR. Organometallics  1982,  1:  485 
    CrossrefGoogle Scholar
  • 22b Anderson PA. Deacon GB. Haarmann KH. Keene FR. Meyer TJ. Reitsma DA. Skelton BW. Strouse GF. Thomas NC. Treadway JA. White AH. Inorg. Chem.  1995,  34:  6145 
    CrossrefGoogle Scholar
  • For staurosporine, see:
  • 23a Rüegg UT. Burgess GM. Trends Pharm. Sci.  1989,  10:  218 
    CrossrefGoogle Scholar
  • 23b Tamaoki T. Nakano H. Nature Biotechnol.  1990,  8:  732 
    CrossrefGoogle Scholar
  • 23c Omura S. Sasaki Y. Iwai Y. Takeshima H. J. Antibiot.  1995,  48:  535 
    CrossrefGoogle Scholar
  • For indolocarbazole protein kinase inhibitors, see:
  • 24a Kase H. Iwahashi K. Nakanishi S. Matsuda Y. Yamada K. Takahashi M. Murakata C. Sato A. Kaneko M. Biochem. Biophys. Res. Commun.  1987,  142:  436 
    CrossrefGoogle Scholar
  • 24b Martiny-Baron G. Kazanietz MG. Mischak H. Blumberg PM. Kochs G. Hug H. Marme D. Schachtele C. J. Biol. Chem.  1993,  268:  9194 
    CrossrefGoogle Scholar
  • 24c Caravatti G. Meyer T. Fredenhagen A. Trinks U. Mett H. Fabbro D. Bioorg. Med. Chem. Lett.  1994,  4:  399 
    CrossrefGoogle Scholar
  • 24d Prudhomme M. Curr. Pharm. Des.  1997,  3:  265 
    CrossrefGoogle Scholar
  • 24e Jackson JR. Gilmartin A. Imburgia C. Winkler JD. Marshall LA. Roshak A. Cancer Res.  2000,  60:  566 
    CrossrefGoogle Scholar
  • 24f Pindur U. Kim YS. Mehrabani F. Curr. Med. Chem.  1999,  6:  29 
    CrossrefGoogle Scholar
  • 24g Slater MJ. Cockerill S. Baxter R. Bonser RW. Gohil K. Gowrie C. Robinson JE. Littler E. Parry N. Randall R. Snowden W. Bioorg. Med. Chem.  1999,  7:  1067 
    CrossrefGoogle Scholar
  • For co-crystal structures of staurosporine with protein kinases, see for example:
  • 25a Toledo LM. Lydon NB. Structure (London)  1997,  5:  1551 
    CrossrefGoogle Scholar
  • 25b Lawrie AM. Noble MEM. Tunnah P. Brown NR. Johnson LN. Endicott JA. Nature Struct. Biol.  1997,  4:  796 
    CrossrefGoogle Scholar
  • 25c Prade L. Engh RA. Girod A. Kinzel V. Huber R. Bossemeyer D. Structure (London)  1997,  5:  1627 
    CrossrefGoogle Scholar
  • 25d Jacobs MD. Black J. Futer O. Swenson L. Hare B. Fleming M. Saxena K. J. Biol. Chem.  2005,  280:  13728 
    CrossrefGoogle Scholar
  • 26 Huwe A. Mazitschek R. Giannis A. Angew. Chem. Int. Ed.  2003,  42:  2122 
    CrossrefGoogle Scholar
  • A related approach was used to synthesize granulatimides:
  • 27a Yoshida T. Nishiyachi M. Nakashima N. Murase M. Kotani E. Chem. Pharm. Bull.  2002,  50:  872 
    CrossrefGoogle Scholar
  • 27b Yoshida T. Nishiyachi M. Nakashima N. Murase M. Kotani E. Chem. Pharm. Bull.  2003,  51:  209 
    CrossrefGoogle Scholar
  • A related cycloruthenation of 2-pyridylindoles and 2-pyridylpyrroles has been reported. See:
  • 28a Thummel RP. Hedge V. J. Org. Chem.  1989,  54:  1720 
    CrossrefGoogle Scholar
  • 28b Wu F. Chamchoumis CM. Thummel RP. Inorg. Chem.  2000,  39:  584 
    CrossrefGoogle Scholar
  • Crystal structures of organometallic compounds bound to enzymes:
  • 29a Heine A. Stura EA. Yli-Kauhaluoma JT. Gao C. Deng Q. Beno BR. Houk KN. Janda KD. Wilson IA. Science  1998,  279:  1934 
    CrossrefGoogle Scholar
  • 29b Di Gleria K. Nickerson DP. Hill HAO. Wong L.-L. Fülöp V. J. Am. Chem. Soc.  1998,  120:  46 
    CrossrefGoogle Scholar
  • 29c McNae IW. Fishburne K. Habtemariam A. Hunter TM. Melchart M. Wang F. Walkinshaw MD. Sadler PJ. Chem. Commun.  2004,  1786 
    CrossrefGoogle Scholar
  • For attractive interactions between organic fluorine and carbonyl groups, see:
  • 30a Hof F. Scofield DM. Schweizer WB. Diederich F. Angew. Chem. Int. Ed.  2004,  43:  5056 
    CrossrefGoogle Scholar
  • 30b Olsen JA. Banner DW. Seiler P. Wagner B. Tschopp T. Obst-Sander U. Kansy M. Müller K. Diederich F. ChemBioChem  2004,  5:  666 
    CrossrefGoogle Scholar
  • 31 Paulini R. Müller K. Diederich F. Angew. Chem. Int. Ed.  2005,  44:  1788 
    CrossrefGoogle Scholar
  • Wnt signaling:
  • 32a Morin PJ. BioEssays  1999,  21:  1021 
    CrossrefGoogle Scholar
  • 32b Cohen P. Frame S. Nature Rev. Mol. Cell Biol.  2001,  2:  769 
    CrossrefGoogle Scholar
  • 32c Jope RS. Johnson GVW. Trends Biochem. Sci.  2004,  29:  95 
    CrossrefGoogle Scholar
  • 33 Zhang F. Phiel CJ. Spece L. Gurvich N. Klein PS. J. Biol. Chem.  2003,  278:  33067 
    CrossrefGoogle Scholar
  • 34 For kenpaullone, see: Leost M. Schultz C. Link A. Wu Y.-Z. Biernat J. Mandelkow E.-M. Bibb JA. Snyder GL. Greengard P. Zaharevitz DW. Gussio R. Senderowicz AM. Sausville EA. Kunick C. Meijer L. Eur. J. Biochem.  2000,  267:  5983 
    CrossrefPubMedGoogle Scholar
  • 35 For BIO, see: Meijer L. Skaltsounis A.-L. Magiatis P. Polychronopoulos P. Knockaert M. Leost M. Ryan XP. Vonica CA. Brivanlou A. Dajani R. Crovace C. Tarricone C. Musacchio A. Roe SM. Pearl L. Greengard P. Chem. Biol.  2003,  10:  1255 
    CrossrefGoogle Scholar
  • Effects of LiCl on the development of Zebrafish embryos:
  • 36a Stachel SE. Grunwald DJ. Myers PZ. Development (Cambridge, UK)  1993,  117:  1261 
    Google Scholar
  • 36b Driever W. Curr. Opin. Gen. Dev.  1995,  5:  610 
    Google Scholar
  • 36c Van de Water S. van de Wetering M. Joore J. Esseling J. Bink R. Clevers H. Zivkovic D. Development (Cambridge, UK)  2001,  128:  3877 
    Google Scholar
  • Effects of LiCl on the development of Xenopus embryos:
  • 37a Busa WB. Gimlich RL. Dev. Biol.  1989,  132:  315 
    Google Scholar
  • 37b Klein PS. Melton DA. Proc. Natl. Acad. Sci. U.S.A.  1996,  93:  8455 
    Google Scholar
  • 37c Heasman J. Development (Cambridge, UK)  1997,  124:  4179 
    Google Scholar
  • For p53-induced apoptosis, see:
  • 38a Levine AJ. Cell  1997,  88:  323 
    CrossrefGoogle Scholar
  • 38b Vousden KH. Lu X. Nature Rev. Cancer  2002,  2:  594 
    CrossrefGoogle Scholar
  • For the role of MDM2 in deactivating p53, see:
  • 39a Momand J. Zambetti GP. Olson DC. George D. Levine AJ. Cell  1992,  69:  1237 
    CrossrefGoogle Scholar
  • 39b Honda R. Tanaka H. Yasuda H. FEBS Lett.  1997,  420:  25 
    CrossrefGoogle Scholar
  • 39c Tovar C. Rosinski J. Filipovic Z. Higgins B. Kolinsky K. Hilton H. Zhao X. Vu BT. Qing W. Packman K. Myklebost O. Heimbrook DC. Vassilev LT. Proc. Natl. Acad. Sci. U.S.A.  2006,  103:  1888 
    CrossrefGoogle Scholar
  • 40a Watcharasit P. Bijur GN. Song L. Zhu J. Chen X. Jope RS. J. Biol. Chem.  2003,  278:  48872 
    CrossrefGoogle Scholar
  • 40b Kulikov R. Boehme KA. Blattner C. Mol. Cell. Biol.  2005,  25:  7170 
    CrossrefGoogle Scholar
  • 41 Pharmacologic modulation of GSK-3β promotes p53-dependent apoptosis in colorectal cancer cells: Tan J. Zhuang L. Leong H.-S. Iyer NG. Liu ET. Yu Q. Cancer Res.  2005,  65:  9012 
    CrossrefGoogle Scholar
  • 42 Hom RK. Chi DY. Katzenellenbogen JA. J. Org. Chem.  1996,  61:  2624 
    CrossrefGoogle Scholar
  • 43 Streu C. Meggers E. Angew. Chem. Int. Ed.  2006,  45:  5645 
    CrossrefPubMedGoogle Scholar
3

We are here using a more general definition of the term ‘organometallic’ which includes all metal/organic hybrid compounds without restriction to substances with metal-carbon bonds.